AI-Driven Genomics
for Pharma
We Deliver a Thorough Understanding of the Genetic Drivers of Disease
NEW REPORT: Key Findings from the Genomic Landscape for ALS
Learn how Genomenon’s comprehensive ALS dataset uncovered compelling trends in Age at Onset and Rate of Disease Progression.
| READ THE REPORT |
Pharma companies need comprehensive genomic information to drive successful precision medicine programs, but decisions are often made using only a fraction of the data available…about 10%
GENOMENON DELIVERS 100% OF THE DATA
5X More Variants in Weeks
Genomenon identified all of the genomic drivers in TARDBP associated with ALS in just two weeks…a yield of 435% more than the number of disease-causing variants found in ClinVar
Comprehensive
Don’t miss anything – get insight into every genomic biomarker published in the medical literature
Evidence-Based
Every scientific assertion is supported by empirical evidence from the medical literature
TALK TO US ABOUT YOUR GENOMIC DATA NEEDS
De-Risk Your Precision Medicine Program
FIND & VALIDATE THE RIGHT TARGETS FASTER
Identify all genetic drivers of a disease or pathway and pinpoint which variants are known to be pathogenic
IDENTIFY THE RIGHT PATIENTS FOR YOUR TRIAL
Expand patient population and identify therapies known to be efficacious with comprehensive biomarker information
DE-RISK & PRIORITIZE INVESTMENT DECISIONS
Accelerate the decision-making process, validate promising research, and eliminate false targets
Learn how a leading rare disease pharma company leveraged genomics to target their clinical trials.
Genomenon Genomic Landscapes provide the complete picture of a disease or pathway with a unique 2-pronged approach
AI-Driven
Genomenon’s Computational Intelligence organizes and indexes all medical evidence and makes it easily searchable
Expertly Curated
Genomenon’s Experts assess the variants for clinical effect, score for pathogenicity, and review to ensure data quality
ALS GENOMIC LANDSCAPE NOW AVAILABLE!
Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.
Genomenon’s methodology improved the efficiency and completeness of our literature review process.